Back to the Top
>Does any one aware of any in vitro or in vivo data on Prozac's
>cytochrome P450 enzyme inhibition profile?
>There are pk reports in the literature indicated fluoxetine and
>norfluoxetine as inhibitors of CYP2D6 and 3A4. Yet, I don't know how
>convincing these data were.
from: "Liao, Sam [PRI]"
Back to the Top
The January, 1997 issue of "Psychiatry Drug Alerts" warns of dystonia in an
adolescent female who had previously been abusing amphetamines and who was
subsequently treated with Prozac for depression. The suggested MOA was
dopamine depletion caused by the amphetamines. I am the consulting
pharmacist for a residential treatment center with a large population of
adolescents currently treated with Prozac and other SSRI's. In September,
1996 we had an ADR reported in a 17 yo male resident on Prozac 20mg for 38
days. The only other med he was taking concurrently was Zantac.His dystonia
was severe enough to require STAT doses of diphenhydramine and benztropine
IM.I would greatly appreciate input as to suggested mechanisms for these
interactions and any other anecdotal reports of dystonia in this age group.
At 12:35 PM 2/3/97 -0600, you wrote:
>PharmPK - Discussions about Pharmacokinetics
> Pharmacodynamics and related topics
>>Does any one aware of any in vitro or in vivo data on Prozac's
>>cytochrome P450 enzyme inhibition profile?
>>There are pk reports in the literature indicated fluoxetine and
>>norfluoxetine as inhibitors of CYP2D6 and 3A4. Yet, I don't know how
>>convincing these data were.
>from: "Liao, Sam [PRI]"
>Also see: http://www.cpb.uokhsc.edu/pkin/pkin.html
PharmPK Discussion List Archive Index page
Copyright 1995-2010 David W. A. Bourne (firstname.lastname@example.org)